Akums Drugs & Pharmaceuticals Ltd. has announced the launch of the world’s first Lasmiditan dispersible tablets, marking an important step forward in the treatment of acute migraine. The DCGI-approved ...
A major advancement in neurological care has arrived with the launch of the world’s first Lasmiditan dispersible tablets. Designed for the acute treatment of migraine, this new formulation addresses a ...
Business Wire: ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV
Dolutegravir is the first integrase inhibitor available as a dispersible tablet for oral suspension for children weighing at least 3kg and from four weeks of age. The FDA approval is testament to the ...
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV
Pharmabiz: EMA committee recommends marketing approval for ViiV Healthcare’s dispersible-tablet, Tivicay to treat children living with HIV
EMA committee recommends marketing approval for ViiV Healthcare’s dispersible-tablet, Tivicay to treat children living with HIV
Nippon India Mutual Fund is one of the leading mutual fund houses and has been one of the preferred choices among the millions of progressive investors.To make investment in mutual fund Scheme easier, we offer online transact service. With it, you can now invest on Nippon India mutual fund Scheme (s) from any place and at anytime without any ...
Healio: FDA approves dispersible tablet formulation of Tivicay for HIV in infants, children